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Abstract
Background. Skin hyperpigmentation in end-stage renal
disease (ESRD) patients has been attributed to the accu-
mulation of middle-molecular-weight (MMW) substances.
Although anMMWmechanism suggests that hyperpigmen-
tation may be improved by high-flux haemodialysis (HF-
HD) and haemodiafiltration (HDF), this possibility has not
been explored. In the present study, we investigated the im-
pact of different dialysis modalities on skin colour in HD
patients.
Methods. Eighty-two ESRD patients on HD were divided
into low-flux HD (LF-HD), HF-HD and HDF groups. The
melanin index (MI) and erythema index (EI) of the ab-
domen and the flexor side of the forearm (non-sun-exposed
areas) and the forehead (sun-exposed area)were determined
by using a narrow-band reflectance spectrophotometer at
baseline and after 12 months.
Results. Even though absolute values of baseline and
follow-up MI and EI of the three sites were comparable
among the three groups, forehead MI and EI were sig-
nificantly decreased after 12 months in the HDF group
(P < 0.05). In addition, the change in forehead MI was
significantly greater in the HDF than in the LF-HD group
(−1.0± 2.4% versus 0.3± 1.6%, P< 0.05). Moreover, β2-
microglobulin reduction rates were negatively correlated
with both changes in forehead MI (P < 0.01) and EI
(P < 0.05).
Conclusions. Skin colour of sun-exposed areas was signi-
ficantly decreased inESRDpatients receivingHDF therapy,
suggesting that enhanced removal of MMW substances by
convectionmay prevent or reduce hyperpigmentation inHD
patients.
Keywords: β2-microglobulin; haemodiafiltration; hyperpigmentation;
low-flux haemodialysis; spectrophotometer
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Introduction
Skin hyperpigmentation is a common finding in patients
with end-stage renal disease (ESRD) [1–5]. Even though
the precise pathophysiologic mechanisms of skin hyperpig-
mentation in ESRD patients have not been fully explored,
the accumulation of middle-molecular-weight molecules,
such as urochrome pigments, carotenoids and α- and
β-melanocyte-stimulating hormone, is thought to play a role
[6–11]. Because the clearance of middle-molecular-weight
molecules is higher during high-flux haemodialysis (HF-
HD) and haemodiafiltration (HDF) [12,13], it is likely that
hyperpigmentation may be improved by these procedures;
however, this possibility has not yet been investigated.
Although most previous studies examining skin pigmen-
tation during dialysis were performed in haemodialysis pa-
tients treated with low-flux dialyzers [8–10,14,15], some
recent studies have examined skin colour in ESRD patients
receiving HF-HD or HDF. Lin et al. [16] demonstrated
an improvement in skin pigmentation in ESRD patients
after the frequency of on-line HDF had been increased;
however, skin colour was not measured using objective
methods. Although a study by Lai et al. [17] included pa-
tients receiving HF-HD and HDF, they performed only a
cross-sectional measurement of skin colour. Even though
peritoneal dialysis (PD) is known to more effectively clear
middle-molecular-weight uraemic toxins, they failed to find
any difference in skin colour between HD and PD patients.
Since visual evaluation of skin colour is highly subjec-
tive and is influenced by ambient light, an objective mea-
surement is necessary to accurately determine changes in
skin colour [18]. In this prospective study, we compared
changes in skin colour, determined by a narrow-band re-
flectance spectrophotometer, among patients receiving dif-
ferent modalities of haemodialysis.
Methods
Subjects
We recruited stable ESRD patients on maintenance HD at Yonsei Uni-
versity Health System, Seoul, Korea. Inclusion criteria were patients be-
tween 18 and 80 years of age who had been on three times weekly HD
for at least 6 months. We excluded patients with any of the following:
signs of acute illness; pre-existing skin disorders; history of taking poten-
tially depigmenting or hyperpigmenting drugs [19]; history of cosmetic
procedures; average haematocrit levels <27%; jaundice; or average fer-
ritin levels >800 ng/mL.
The three groups of patients included those on low-flux haemodialysis
(LF-HD), HF-HD and on-line HDF. Patients receiving HF-HD and HDF
were switched from LF-HD within 3 months before inclusion. LF-HD
patients received dialysis with a Fresenius 5008 dialysis system (Frese-
nius Medical Care, Bad Homburg, Germany) using a dialyser contain-
ing a polyamide blend membrane (Polyflux 17L R©, Gambro, Hechingen,
Germany). HF-HD and HDF were performed three times a week with the
same machine using a polyamide blend or a polysulfone membrane dia-
lyzer (Polyflux 17S R©, Gambro; FX50 R©, FX60 R©, FX80 R©, or HF80S R©,
Fresenius Medical Care). Standard bicarbonate-based dialysates with ul-
trapure water were used for all patients, and treatment times were individ-
ualized for each patient and left unchanged throughout the study.
Biochemical and haematologic tests were performed monthly at mid-
week before the dialysis session, and the mean values during the 12-month
study period were calculated for each patient. The serum concentrations
of high-sensitivity CRP (hsCRP) were determined by the latex-enhanced
immunonephelometric method every 3 months, and the mean values dur-
ing the 12-month study period were used for analysis. Hepatitis B virus
surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV) were
checked every 6 months. At the end of the study, serum β2-microglobulin
(β2-MG) concentrations were determined by an automated immunochem-
ical analyser (PAMIA-40i, Sysmex Corp., Kobe, Japan) both before and
after the midweek dialysis session. Post-dialysis β2-MG levels were ex-
pressed after correcting for haemoconcentration as previously described
[20]. β2-MG reduction rates (β2-MG RR), based on pre- and post-dialysis
β2-MG concentrations, were calculated as follows:
β2-MG RR(%) = [(Pre-dialysis β2-MG − Post-dialysis
β2-MG)/Pre-dialysis β2-MG] × 100.
Skin colour measurements
Skin colour was assessed using a narrow-band reflectance spec-
trophotometer (Mexameter MX16, Courage-Khazaka Electronic, Ko¨ln,
Germany) that emits light at three defined wavelengths [568 nm (green),
660 nm (red) and 880 nm (infrared)] and measures absorbed and reflected
light at wavelengths for haemoglobin (green and red) and melanin (red
and near-infrared) [21]. The melanin index was automatically computed
from the intensities of absorbed and reflected light at 660 and 880 nm,
respectively, while the erythema index was computed from the inten-
sities of absorbed and reflected light at 568 and 660 nm, respectively.
Mexameter readings ranged from 1 to 1000, with higher melanin
and erythema indices representing darker and more erythematous skin,
respectively.
Skin colour measurements were performed according to manufacturer
instructions by the same physician just before themidweek dialysis session
at the start of the study (October 2006) and after 12 months (October
2007). These measurements were taken at three skin sites: the abdomen,
the flexor side of the forearm (non-sun-exposed) and the forehead (sun-
exposed). For each site, five measurements were carried out and the mean
value was used for analysis.
This study was approved by the Institutional Review Board for Human
Research at Yonsei University College of Medicine, and informed consent
was obtained from all patients.
Statistical analysis
All values are expressed as means ± standard deviations (SD) or percent-
ages. Statistical analysis was performed using SPSS for Windows Version
13.0 (SPSS, Inc., Chicago, IL, USA). Results were analysed using appro-
priate ANOVA, paired t-tests or chi-square tests. Significant differences
found by ANOVA were further confirmed by Student’s t-test with the
Bonferroni correction. Correlations between changes in the melanin and
erythema indices and β2-MG RR were determined by Pearson’s correla-
tion analysis, and independent factors associated with the changes in the
melanin index were determined by multiple linear regression analysis and
multivariate logistic regression analysis. P-values <0.05 were considered
to be statistically significant.
Results
Demographic characteristics and laboratory findings
We analysed data from 82 ESRD patients (Figure 1). The
mean age of the patients was 56.0 ± 12.6 years and the
sex ratio (M:F) was 0.8:1. The mean dialysis duration was
65.9 ± 48.3 months. The LF-HD group included 26 pa-
tients, the HF-HD group had 29 patients and the HDF group
had 27 patients. Dialysis duration in the HDF group (73.4±
52.4months) tended to be longer than in the LF-HD (59.7±
34.2 months) and HF-HD (65.0 ± 59.4 months) groups,
but this difference was not significant. There were no dif-
ferences in the mean age, sex ratio, underlying disease of
ESRD or the proportion of patients with positive HBsAg or
anti-HCV among the three groups. The mean haemoglobin
levels, serum calcium and phosphorus concentrations,
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Fig. 1. Participant flow chart.
Table 1. Clinical characteristics and laboratory findings of the patients
LF-HD HF-HD HDF
(n = 26) (n = 29) (n = 27)
Age (years) 59.4 ± 13.5 56.1 ± 15.0 57.6 ± 7.3
Sex (M:F) 12:14 12:17 13:14
Haemodialysis duration
(months)
59.7 ± 24.2 65.0 ± 59.4 73.4 ± 52.4
Hepatitis (B or C virus) 4 (15.4%) 3 (10.3%) 5 (18.5%)
Cause of ESRD
Diabetic nephropathy 15 (57.7%) 15 (51.7%) 13(48.1%)
Chronic
glomerulonephritis
4 (15.4%) 4 (13.8%) 4 (14.8%)
Hypertensive
nephrosclerosis
1 (3.8%) 2 (6.9%) 3 (11.1%)
Polycystic kidney
disease
0 (0.0%) 2 (6.9%) 2 (7.4%)
Others/causes
unknown
6 (23.1%) 6 (20.7%) 5 (18.5%)
Kt/V urea 1.6 ± 0.2 1.6 ± 0.3 1.7 ± 0.3
Haemoglobin (g/dL) 10.4 ± 1.1 10.5 ± 1.1 10.7 ± 1.3
Calcium (mg/dL) 8.9 ± 0.9 9.0 ± 0.7 8.8 ± 0.8
Phosphorus (mg/dL) 5.2 ± 1.1 4.6 ± 1.3 5.1 ± 1.2
Albumin (g/dL) 4.1 ± 0.4 4.1 ± 0.4 4.2 ± 0.4
Total bilirubin (mg/dL) 0.4 ± 0.3 0.3 ± 0.1 0.4 ± 0.1
Ferritin (ng/mL) 248.8 ± 137.4 195.4 ± 142.5 237.9 ± 135.1
hsCRP (mg/L) 4.71 ± 2.71 5.20 ± 2.65 4.45 ± 2.09
Values are means ± SD or numbers (percent).
LF-HD, low-flux haemodialysis; HF-HD, high-flux haemodialysis; HDF,
haemodiafiltration; hsCRP, high sensitivity C-reactive protein.
serum albumin, total bilirubin, ferritin and hsCRP levels
were also comparable (Table 1). In addition, there were no
differences in these values at the start and at the end of the
study among the three groups (data not shown).
Skin colour measurements
As seen in Table 2, there were no differences in baseline
melanin and erythema indices of the abdomen, forearm or
forehead among the three groups, and the absolute values of
Table 2. Baseline and follow-up melanin and erythema indices of the
patients
LF-HD HF-HD HDF
Baseline melanin
index
Forehead 498.5 ± 18.4 500.6 ± 23.8 500.2 ± 27.2
Forearm 489.8 ± 15.7 487.3 ± 16.9 493.3 ± 22.6
Abdomen 469.3 ± 20.0 474.3 ± 18.2 474.1 ± 23.7
Melanin index after
12 months
Forehead 500.1 ± 18.7 497.4 ± 17.3 495.1 ± 21.9∗
Forearm 487.5 ± 16.5 487.7 ± 16.7 490.0 ± 17.3
Abdomen 471.2 ± 22.1 474.0 ± 16.9 475.1 ± 22.4
Changes in the
melanin index (%)
Forehead 0.3 ± 1.6 −0.6 ± 2.6 −1.0 ± 2.4#
Forearm −0.4 ± 2.5 −0.1 ± 2.0 −0.6 ± 1.8
Abdomen 0.4 ± 2.7 −0.1 ± 2.0 0.5 ± 2.4
Baseline erythema
index
Forehead 610.1 ± 24.9 613.8 ± 22.8 614.7 ± 26.4
Forearm 587.0 ± 17.6 586.2 ± 23.5 589.5 ± 23.6
Abdomen 571.7 ± 14.4 575.8 ± 20.9 572.2 ± 32.2
Erythema index after
12 months
Forehead 609.0 ± 23.3 608.8 ± 18.4 604.7 ± 23.4∗
Forearm 584.6 ± 12.7 587.6 ± 17.7 586.6 ± 19.5
Abdomen 569.5 ± 15.3 573.1 ± 17.3 573.6 ± 16.1
Changes in the
erythema index (%)
Forehead −0.1 ± 2.5 −0.8 ± 2.4 −1.6 ± 2.5#
Forearm −0.4 ± 1.9 0.0 ± 2.6 −0.4 ± 3.2
Abdomen −0.4 ± 1.8 −0.4 ± 2.5 0.4 ± 5.5
Values are means ± SD.
LF-HD, low-flux haemodialysis; HF-HD, high-flux haemodialysis; HDF,
haemodiafiltration.
∗P < 0.05 versus baseline; #P < 0.05 versus LF-HD.
these indices after 12 months were also comparable. How-
ever, in theHDFgroup,melanin and erythema indices of the
foreheadwere significantly decreased after 12months com-
pared with baseline values (P< 0.05). In addition, changes
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Fig. 2. Changes in melanin (A) and erythema indices (B) of the forehead in the LF-HD, HF-HD and HDF groups. Compared to the LF-HD group,
changes in melanin and erythema indices were significantly lower in HDF patients. Changes in the forehead melanin and erythema indices in the
HF-HD group were intermediate. ∗P < 0.05 versus the LF-HD group.
Fig. 3. Pre-dialysis β2-microglobulin (MG) concentrations (A) and β2-MG reduction rates (RR) (B) in the LF-HD, HF-HD and HDF groups. Pre-
dialysis β2-MG concentrations were significantly lower in the HDF group relative to the LF-HD group. In contrast, β2-MG RR was significantly higher
in the HDF group than in the HF-HD and LF-HD groups. ∗P < 0.01 versus the LF-HD group; #P < 0.005 versus other groups; †P < 0.0001 versus the
LF-HD group.
in the forehead melanin index were significantly greater in
HDF than in LF-HD patients (−1.0 ± 2.4% versus 0.3 ±
1.6%, P < 0.05). After 12 months, the erythema index
of the forehead showed a decrease from baseline in all
three groups, and this decrease was significantly greater in
the HDF group (−1.6 ± 2.5%) than in the LF-HD group
(−0.1 ± 2.5%) (P < 0.05). Changes in the melanin and
erythema indices of the forehead in the HF-HD group were
intermediate (Figure 2).
We found no differences inmelanin and erythema indices
of abdomen and forearm among the three groups.
Pre-dialysis β2-MG concentrations and β2-MG RR
Pre-dialysis β2-MG concentrations were significantly
higher in the LF-HD group (41.5 ± 8.5 mg/L) than in
the HDF group (33.2 ± 6.3 mg/L) (P < 0.01). In contrast,
β2-MG RR was higher in the HDF (65.1 ± 11.2%) group
than in the HF-HD (42.9± 13.1%) (P< 0.005) and LF-HD
groups (2.5 ± 5.1%) (P < 0.0001) (Figure 3).
Correlations between changes in melanin and erythema
indices and β2-MG RR
Pearson’s correlation analysis revealed that there were sig-
nificant negative correlations between the changes in the
melanin and erythema indices of the forehead and β2-
MGRR (melanin index, R = −0.348, P < 0.01; erythema
index, R = −0.265, P < 0.05) (Figure 4). In contrast,
changes in melanin and erythema indices of the abdomen
and forearm did not correlate with β2-MG RR (data not
shown). There were no correlations between changes in
skin colour and patient age, dialysis duration, serum albu-
min, or hsCRP levels.
Independent factors associated with changes
in the forehead melanin index
Multiple linear regression and multivariate logistic regres-
sion analyses were performed to identify the independent
factors associated with the change in the forehead melanin
index. During initial analysis, multiple linear regression
analysis revealed that both HF-HD (P < 0.05) and HDF
(P < 0.005) were independently associated with changes
in the forehead melanin index, while the presence of
hepatitis B or C, sex, age, dialysis duration, serum albu-
min and hsCRP levels had no effect on the changes in the
forehead melanin index (Table 3). Patients were then di-
vided into two groups for multivariate logistic regression
analysis: Group 1 consisted of patients with an increased
melanin index after 12 months and Group 2 included pa-
tients with a decreased melanin index after 12 months. This
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Fig. 4. Correlations between changes in the forehead melanin (A) and erythema (B) indices and β2-microglobulin reduction rates (β2-MG RR).
Pearson’s correlation analysis revealed significant negative correlations between the changes in the melanin and erythema indices and the β2-MG RR.
Table 3. Multiple linear regression of independent factors associated with
changes in the forehead melanin index
β P-value R2
Dialysis modality
HF-HD (versus LF-HD) −1.077 <0.05
HDF (versus LF-HD) −1.603 <0.005
Presence of hepatitis B or C −0.228 0.648
Sex (versus male) −0.606 0.092 0.193
Age (per year) −0.024 0.104
Dialysis duration (per month) 0.001 0.775
Albumin (per g/dL) −0.065 0.897
hsCRP (per mg/L) 0.022 0.282
LF-HD, low-flux haemodialysis; HF-HD, high-flux haemodialysis; HDF,
haemodiafiltration; hsCRP, high sensitivity C-reactive protein.
Table 4. Multivariate logistic regression of factors associated with
decreases in the forehead melanin index
OR 95% CI P-value
Dialysis modality
HF-HD (versus LF-HD) 3.18 0.84–12.05 0.084
HDF (versus LF-HD) 3.60 1.11–11.64 <0.05
Presence of hepatitis B or C 1.14 0.29–4.36 0.85
Sex (versus male) 0.81 0.31–2.10 0.65
Age (per year) 1.02 0.98–1.06 0.37
Dialysis duration (per month) 1.00 0.99–1.01 0.78
Albumin (per g/dL) 1.19 0.29–4.94 0.81
hsCRP (per mg/L) 1.04 0.59–1.81 0.90
LF-HD, low-flux haemodialysis; HF-HD, high-flux haemodialysis; HDF,
haemodiafiltration; hsCRP, high sensitivity C-reactive protein; CI, confi-
dence interval; OR, odds ratio.
analysis showed that decreases in the forehead melanin in-
dex were associated with dialysis modality but not with the
presence of hepatitis B or C, sex, age, dialysis duration,
serum albumin or hsCRP levels (Table 4).
Discussion
Skin hyperpigmentation is a common clinical finding in
ESRD patients undergoing dialysis [1–5] and can lead to
cosmetic and psychological concerns [22,23]. Retention of
middle-molecular-weight molecules, such as urochromic
pigments, carotenoids and α- and β-melanocyte-stimulating
hormone, has been implicated in the pathogenesis of diffuse
pigmentation in ESRD patients [6–11]. However, changes
in skin colour have been largely unexplored in patients on
HDF, in whom middle-molecular-weight molecular clear-
ance is significantly higher compared to conventional LF-
HD [12,13]. In this study, we demonstrated for the first
time that hyperpigmentation was significantly improved in
patients on HDF, whereas skin colour was not altered in LF-
HD patients. These findings indicate that enhanced removal
of middle-molecular-weight substances by convective ther-
apy may reduce skin hyperpigmentation in ESRD patients.
Most prior investigations examining skin colour during
ESRDwere observational studies in patients on LF-HD, and
these demonstrated that skin colourwas significantly darker
in dialysis patients compared to controls [8–10,14,15]. In
contrast, skin colour in patients treated with HF-HD, HDF
and PD, which are known to be more effective in removing
middle-molecular-weight uraemic toxins, has been largely
unexplored. Lin et al. [16] examined changes in skin colour
in 111 ESRD patients and observed less hyperpigmenta-
tion during increased frequency of on-line HDF; however,
they did not measure skin colour using objective meth-
ods. Recently, Lai et al. [17] evaluated the skin colour of
the abdomen (non-sun-exposed site) and the forearm (sun-
exposed site) in 59 healthy controls, in 51 patients on HD
(including HF-HD and HDF) and in 73 PD patients by
using a reflected-light colorimeter. Skin colour in the non-
sun-exposed area was significantly darker in patients with
ESRD compared to controls, while skin brightness in sun-
exposed sites was not different between ESRD patients and
controls. In addition, HD and PD patients had similar skin
colour in both non-sun-exposed and sun-exposed skin ar-
eas. Even though skin colour was quantified objectively in
this cross-sectional observational study, the authors did not
examine changes in skin colour according to the modality
of dialysis.
The present study is the first to prospectively investi-
gate the impact of dialysis modality on skin colour in
HD patients. In May 2006, a new HD centre at Yonsei
University Health System was opened with new HD ma-
chines, which made the present investigation possible. The
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on January 22, 2014
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
2808 S. J. Moon et al.
patients in our study, however, could not be randomized
due to the 25% higher cost of HF-HD and HDF treatments
(compared to LF-HD). In spite of this, we found no signifi-
cant differences in baseline demographic characteristics or
laboratory findings among the three groups and found that
the baseline melanin and erythema indices were also com-
parable. During the study period, we found that the melanin
index of the forehead significantly decreased in patients
undergoing HDF. In addition, HDF patients had a signifi-
cantly greater percentage change (decrease) in the forehead
melanin index than HDF and LF-HD patients, whereas the
indices of the non-sun-exposed sites were comparable be-
tween the two groups. Moreover, there was a significant
negative correlation between the changes in melanin and
erythema indices and the β2-MG RR, which represents
middle-molecular-weight molecular clearance, while the
changes in skin colour on the abdomen and forearm did not
correlate with the β2-MG RR. Based on these findings, we
suggest that some middle-molecular-weight uraemic sub-
stances, which can largely be removed by HDF, may stimu-
late melanogenesis under sunlight, whereas hyperpigmen-
tation of non-sun exposed areas may be largely attributed to
certain large-molecular-weight substances, such as protein-
bound 3,4-dihydroxyphenylalanine (PB-DOPA) and PB-5-
S-cysteinyldopa (PB-5SCD).
In the current study, baseline skin colour was compa-
rable among the three groups even though initial dialysis
duration was slightly longer in the HDF group than in the
other groups. In addition, dialysis duration did not affect
the changes in the forehead melanin index as assessed
by multiple linear regression and multivariate logistic
regression analyses. These results are in accordance with
most previous studies that have shown that there is no
significant correlation between dialysis duration and skin
hyperpigmentation in ESRD patients [15,17]. In contrast, a
recent study demonstrated that serum levels of free 5SCD,
one of the markers of pigmentation, were positively cor-
related with the duration of HD treatment, suggesting that
skin colour may become darker in ESRD patients with in-
creasing dialysis duration [24]. However, serum-free 5SCD
levels in that study were significantly decreased to one-
fourth of baseline values during each 4-h HD session. Fur-
thermore, there were no significant correlations between
HD duration and the serum levels of other pigmentation
markers, such as pheomelanin, PB-DOPA and PB-5SCD.
Therefore, further study will be needed to clarify whether
free 5SCD is responsible for skin hyperpigmentation in
patients on HD. As an additional mechanism, Takiwaki
et al. [25] demonstrated that topical anti-inflammatory
agents inhibited ultraviolet B-induced erythema and pig-
mentation, implicating inflammation in the pathogenesis
of hyperpigmentation. We therefore determined whether
inflammation status had an effect on skin hyperpigmenta-
tion in our HD patients. Serum albumin and hsCRP levels
were used as markers of inflammation and were included
in the analyses. Pearson’s correlation analysis revealed that
there were no significant correlations between changes
in skin colour and serum albumin and hsCRP levels. In
addition, albumin and hsCRP were not independently
associated with changes in skin colour. Based on these
findings, we suggest that systemic inflammation may
have little effect on skin hyperpigmentation in uraemic
patients.
In conclusion, hyperpigmentation in sun-exposed areas
was significantly improved in ESRD patients receiving
HDF therapy, suggesting that enhanced removal of middle-
molecular-weight substances by convection may prevent or
reduce skin hyperpigmentation in dialysis patients.
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Abstract
Background. Haemodialysis patients were studied in
12 countries to identify practice patterns of prescrip-
tion of antihypertensive agents (AHA) associated with
survival.
Methods. The sample included 28 513 patients enrolled
in DOPPS I and II. The classes of AHA studied were
beta blocker (BB), angiotensin-converting enzyme inhibitor
(ACEI), angiotensin receptor blocker (ARB), peripheral
blocker, central antagonist, vasodilator, long-acting dihy-
dropyridine calcium channel blocker (CCB), short-acting
dihydropyridine CCB and non-dihydropyridine CCB. To
reduce bias due to unmeasured confounders, the associa-
tions with mortality were assessed by separate Cox models
based on patient-level prescription and facility prescription
practice.
Results. An increase in prescription of ARBs (9.5%) and
BBs (9.1%) was observed from DOPPS I to II. Prescription
of AHA classes varied significantly by country, ranging
for BBs from 9.7% in Japan to 52.7% in Sweden and for
ARBs from 5.5% in Italy to 21.3% in Japan in DOPPS II.
Facilities that treated 10% more patients with ARBs had,
on average, 7% lower all-cause mortality, independent of
patient characteristics and the prescription patterns of other
antihypertensive medications (P = 0.05). Significant and
independent associations with reduction in cardiovascular
mortality were observed for ARBs (RR= 0.79; P = 0.005)
and BBs (RR = 0.87, P = 0.004) in analyses of patient-
level prescriptions. These associations in the facility-level
model followed the same direction.
Conclusions. DOPPS data show large variations across
countries in AHA prescription for haemodialysis patients.
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